DURHAM, N.C.--(BUSINESS WIRE)--Argos Therapeutics today announced the initiation of a Phase 2a trial of its AGS-003 therapy, in combination with sunitinib, for the treatment of newly diagnosed advanced renal cell carcinoma (RCC). AGS-003 is a product of the Company’s Arcelis™ technology, which is an immunotherapy platform for creating personalized, RNA-loaded, dendritic cell-based therapies perfectly matched to each patient’s unique tumor burden. In vitro and animal model studies of the impact of sunitinib on the function of dendritic cells and T-cells have indicated evidence of synergistic activity. The aim of the current trial is to confirm these results in a clinical setting.
